Sector consensus Summit Therapeutics Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 19:55:21 21/01/2026 GMT			5-day change	1st Jan Change
16.67 ^USD	+3.80%		-6.69%	-5.83%

01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Average Target P.	Objective/dr gap	Nbr of analysts
SUMMIT THERAPEUTICS INC.			US$24.22	+101.9%	13
ARGENX SE			€824.2	+20.18%	15
WUXI APPTEC CO., LTD.			CN¥129.23	+29.93%	18
INSMED INCORPORATED			US$213.94	+30.84%	18
BIONTECH SE			US$119.16	+30.94%	19
WUXI BIOLOGICS (CAYMAN) INC.			HK$36.58	+10.47%	25
GENMAB A/S			DKK 2,169.71	+8.59%	13
AKESO, INC.			HK$154.06	+46.71%	22
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.			HK$532.76	+20.42%	17
EXELIXIS, INC.			US$45.61	+4.18%	18
MADRIGAL PHARMACEUTICALS, INC.			US$635.21	+25.8%	14
ARROWHEAD PHARMACEUTICALS, INC.			US$78.2	+19.79%	10
NUVALENT, INC.			US$141.71	+33.77%	17
REMEGEN CO., LTD.			HK$76.52	-8.83%	15
CYTOKINETICS, INCORPORATED			US$88.44	+38.67%	18
METSERA, INC.	-	-	-	-	-
Average			351.3	+27.56%	17
Weighted average by Cap.			416.65	+26.94%	17